Publisert 14.06.2021

Subscription rights declared

On March 31st 2021, all investors holding subscription rights from the 2018 share issue declared their subscription rights. VLH Invest AS, Solvik Holding AS, Sierra Invest AS and Bent Eriksen Invest  AS, all declared their rights to buy shares at 17.15 NOK/share.

The new share holdings is found here.


Henrik Lund, CEO

Regenics AS have developed clinical proof of efficacy and safety  in human 2 degree burn wounds for our products Collex® and Vernex®.

The procudts are beeing developed as class III devices. WoundClear® is developed as a BLA/EU CP biotech drug.